Benign Prostatic Hyperplasia (BPH) Procedures are expected to grow at a CAGR of 2.3% during 2017 – 2023, according to P%S Market Research. US Benign Prostatic Hyperplasia Procedures Market Industry Global Key Manufacturers Analysis by Key Company Like NxThera, Inc., Boston Scientific Corporation, Urologix, LLC., Convergent Laser Technologies
Increasing life expectancy and fall in the birth rates are the major reasons for rise in the aging population. The people in this category require extensive care, since they are more prone to illness due to low immunity levels and longer recovery time.
Increase in the aging population in the U.S., Germany, China and India in the next few years, is expected to create high demand for BPH treatment devices, since the population aged 50 years and above is more prone to BPH, and therefore tend to opt for various treatments that involve the use of procedures such as TURP, prostate implants and laser based treatments. Thus, growing aging population acts as a strong driver supporting the increase in the number of BPH procedures performed.
As per the findings of the research, surgical procedure held the largest share in the global BPH procedures, primarily due to increasing prevalence of BPH disorders. The number of laser based procedure is expected to register fastest growth during the forecast period since these procedures are as effective as surgical procedures and reduce the hospital stay time.
Hospitals held the largest share of the number of BPH procedures performed, based on the end user. Ambulatory surgical centers are expected to witness the highest inflow of BPH patients for treatment during the forecast period, due to development of technologically advanced BPH procedures and rising prevalence of BPH disorders leading to the growth in the number of patients treated in the ambulatory surgical centers.
Download Report Sample at: www.psmarketresearch.com/market-…ort-sample
Geographically, Europe accounted for the largest number of BPH procedures done in 2016. Growing ageing population, lower cost of BPH treatment as compared to the U.S., high healthcare spending, and technological advancements in the field of urological procedures technology are some of the factors driving the growth of the BPH procedures in the Europe.
France, Germany and the U.K. are expected to be the most promising countries for the growth in number of the BPH procedures. In June 2016, National Institute of Health and Care Excellence (NICE) approved GreenLight XPS laser treatment for the treatment of BPH.
NICE added that the widespread adoption of the procedure could save the National Health Services (NHS) an estimated $4.3 million (£3 million) a year. Asia-Pacific is expected to witness the high number of BPH procedures performed during the forecast period, owing to the rising prevalence of BPH disorders, increasing disposable income, aging population, and growing efforts to increase awareness about advanced BPH treatment procedures.
Make Enquiry the Report: www.psmarketresearch.com/send-en…procedures
There has been an increase in the use of minimally invasive procedures such as TUIP, laser based treatments, due to which several technological advancements are being done in the field of urology. Various treatment methods, such as the use of Rezum system and pulsed electromagnetic field therapy (PEMF), are being developed for the treatment of BPH.
Rezum system manufactured by NxThera is a device that utilizes radiofrequency energy to create thermal energy in the form of water vapor to destroy excessive prostatic tissue growth caused by BPH, to resolve patient symptoms through a minimally invasive procedure, with few or no side effects.
Key players are in the process of introducing new advanced products for BPH treatment procedures. For instance, in May 2016, Olympus Corporation (Olympus), announced the launch of USFDA cleared Plasma-OvalButton, an addition to the company’s Plasma Loops and electrodes product portfolio that utilizes Olympus’ plasma technology for urologic procedures, including minimally invasive surgery to reduce benign prostate hyperplasia (BPH).
In March 2016, Lumenis Ltd. (Lumenis), announced the expansion of its comprehensive Urology portfolio with the launch of Lumenis Pulse 30H, at the European Association of Urology Congress, in Munich.
Some of the other key players operating in the global BPH procedures include NxThera, Inc., Boston Scientific Corporation, Urologix, LLC., Karl Storz GmbH & Co. KG, Lumenis Ltd., Olympus Corporation, Advin Urology, Convergent Laser Technologies, Richard Wolf GmbH, Medtronic Plc.
Category: Market Research Publishers and RetailersCompany about: Prescient & Strategic (P&S) Intelligence Private Limited (formerly known as P&S Market Research Private Limited) was born out of the idea of helping businesses achieve breakthroughs through intelligent decision making, underpinned by a thorough understanding of industry dynamics. As a market intelligence and consulting firm, we strive to provide our clients with first-string market insights to facilitate intelligent decision making.At P&S Intelligence, we offer a multi-dimensiona ...